3004.90.92.40 - Other
Details
| Field | Value |
|---|---|
| Unit of Quantity | kg |
| General Rate of Duty | Free |
| Special Rate of Duty | N/A |
| Column 2 Rate of Duty | 30% |
| Quota Quantity | N/A |
| Additional Duties | N/A |
Overview
This HTS category, 3004.90.92.40, encompasses "Other" medicaments primarily affecting the central nervous system that are not specifically classified under other subheadings within the "Medicaments primarily affecting the central nervous system" group. These are pharmaceutical products, whether single or mixed, intended for therapeutic or prophylactic uses. They must be presented in measured doses, such as tablets, capsules, or injections, or in forms suitable for retail sale. The defining characteristic of this "Other" designation is that the medicament does not fit neatly into the more specific sibling categories such as analgesics, anticonvulsants, or antidepressants.
To distinguish this category from its siblings, it is crucial to examine the primary pharmacological action of the medicament. While analgesics, antipyretics, and nonhormonal anti-inflammatory agents focus on pain relief and reducing fever, and anticonvulsants, hypnotics, and sedatives target seizure control and sleep induction/relaxation, this "Other" category captures central nervous system medications whose primary function does not align with those specific therapeutic classes. This might include, for example, drugs used for treating neurological disorders not primarily characterized by seizures or pain, or specific types of psychotropic agents not falling under the broader "antidepressants, tranquilizers, and other psychotherapeutic agents" heading.
As this is a leaf node within the HTS structure, there are no further subcategories for this specific code. Therefore, classification into 3004.90.92.40 hinges on the detailed examination of the product's intended use, its chemical composition, and its presentation, ensuring it does not meet the criteria for any more narrowly defined sibling categories under 3004.90.92. This often requires careful review of scientific literature and product information to confirm the primary therapeutic or prophylactic purpose impacting the central nervous system.